You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Cyclooxygenase inhibitor; may be selective for COX-3 (IC50 values are 460, > 1000 and > 1000 μM for canine COX-3, and murine COX-1 and COX-2 respectively). Widely used analgesic and antipyretic agent.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 151.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||6.62 mL||33.08 mL||66.16 mL|
|5 mM||1.32 mL||6.62 mL||13.23 mL|
|10 mM||0.66 mL||3.31 mL||6.62 mL|
|50 mM||0.13 mL||0.66 mL||1.32 mL|
References are publications that support the biological activity of the product.
Chandrasekharan et al (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc.Natl.Acad.Sci.U.S.A. 99 13926 PMID: 12242329
Chong et al (2001) Effect of acetaminophen on atherosclerosis. Ann.Pharmacother. 35 1476 PMID: 11724102
Riendeau et al (1997) Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDS) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can.J.Physiol.Pharmacol. 75 1088 PMID: 9365818
If you know of a relevant reference for Acetaminophen, please let us know.
View Related Products by Product Action
Keywords: Acetaminophen, Acetaminophen supplier, Cyclooxygenase, inhibitors, inhibits, COX-3, Oxygenases, Oxidases, Paracetamol, 1706, Tocris Bioscience
3 Citations for Acetaminophen
Citations are publications that use Tocris products. Selected citations for Acetaminophen include:
Factor et al (2007) Adenosine regulation of alveolar fluid clearance. Proc Natl Acad Sci U S A 104 4083 PMID: 17360481
Inagaki et al (2012) Evaluation of drug-induced tissue injury by measuring alanine aminotransferase (ALT) activity in silkworm hemolymph. J Neurosci 13 13 PMID: 23137391
Liu and Gao (2007) Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect. J Neurophysiol 97 837 PMID: 17093123
Do you know of a great paper that uses Acetaminophen from Tocris? Please let us know.
Reviews for Acetaminophen
There are currently no reviews for this product. Be the first to review Acetaminophen and earn rewards!
Have you used Acetaminophen?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.